NEW YORK (Reuters Health) – Rituximab monotherapy is “a very good option” for severe cryoglobulinemic vasculitis (CV), according to the authors of an Italian study published online December 6 in Arthritis & Rheumatism.
“RTX (rituximab) is superior, also in the long term, to standard...